DRG Market Assessment reports

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K…

Biomarker-driven prescribing is entrenched in indications such as non-small-cell lung cancer (NSCLC) and malignant melanoma and is playing an increasingly important role in indications such as…

Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…

Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/…

Despite the extensive armamentarium of chronic pain therapies, which is increasingly subject to generic competition, the chronic pain market continues to represent a notable commercial…

As the prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase in the United States…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

Immune checkpoint inhibitors (ICIs), including Bristol-Myers Squibb’s Opdivo and Yervoy and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies for several cancers, notably…

In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment…

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL…

Abstract: Hepatocellular carcinoma is the most common form of liver cancer. It is the seventh-most-common type of cancer worldwide and the third-most-common cause of cancer death worldwide. Most…

From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing…